Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 March 2025, 15:30 (CET) to 5 March 2025, 17:00 (CET)

Clinical Trials Information System (CTIS) bitesize talk: Change of sponsor in CTIS, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 March 2025, 15:30 (CET) to 5 March 2025, 17:00 (CET)

Opinion/decision on a Paediatric investigation plan (PIP): Vimpat, lacosamide, decision type: RPM: decision refers to a refusal on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0470/2023

Opinion/decision on a Paediatric investigation plan (PIP): Vimpat, lacosamide, decision type: RPM: decision refers to a refusal on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0470/2023

Opinion/decision on a Paediatric investigation plan (PIP): Saxenda, liraglutide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: P/0468/2023

Opinion/decision on a Paediatric investigation plan (PIP): Saxenda, liraglutide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: P/0468/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xydalba, dalbavancin hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0467/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xydalba, dalbavancin hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0467/2023

Opinion/decision on a Paediatric investigation plan (PIP): Lutathera, lutetium (177Lu) oxodotreotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cys

Opinion/decision on a Paediatric investigation plan (PIP): Lutathera, lutetium (177Lu) oxodotreotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0461/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness